Company Overview
Compass Pathways plc is a biotechnology company developing COMP360, an investigational synthetic psilocybin therapy for mental health conditions including treatment-resistant depression and PTSD.
Key Financial Figures
Based on the consolidated statements of operations, the company reported no Revenue for 2025. The net loss per share (EPS) was $1.00 for the fourth quarter of 2025 and $3.08 for the full year ended December 31, 2025.
Additional Financial Insights
The full-year net loss was $287.9 million, driven significantly by a $122.6 million non-cash loss on warrant liabilities. Annual research and development expenses remained stable at $118.4 million. The company ended 2025 with $149.6 million in cash and cash equivalents.
The post Compass Pathways 2025 Financial Review first appeared on Alphastreet.
